PIPERACILLIN AND TAZOBACTAM

Post-LOE

piperacillin sodium, tazobactam sodium

Sagent Pharmaceuticals

ANDAINJECTIONINJECTABLE

Approved

Feb 2021

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PIPERACILLIN AND TAZOBACTAM (piperacillin sodium, tazobactam sodium) by Sagent Pharmaceuticals is [see microbiology ()] . Approved for older) for the treatment of appendicitis (complicated by rupture, abscess), peritonitis caused by beta-lactamase producing isolates of escherichia coli and 12 more indications. First approved in 2021.

Drug data last refreshed 18h ago

Mechanism of Action

[see Microbiology ()] .

Indications (15)

older) for the treatment of appendicitis (complicated by rupture abscess)peritonitis caused by beta-lactamase producing isolates of Escherichia coli

Worked on PIPERACILLIN AND TAZOBACTAM at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.